205 related articles for article (PubMed ID: 16970400)
1. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
3. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
4. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
7. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
8. Construction and validation of a RET TK catalytic domain by homology modeling.
Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
[TBL] [Abstract][Full Text] [Related]
9. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT; Saccardo MB; Ardini E; Menichincheri M; Rusconi L; Magnaghi P; Orsini P; Avanzi N; Borgia AL; Nesi M; Bandiera T; Fogliatto G; Bertrand JA
Biochemistry; 2010 Aug; 49(32):6813-25. PubMed ID: 20695522
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
14. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
15. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
16. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
17. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Iwahara T; Fujimoto J; Wen D; Cupples R; Bucay N; Arakawa T; Mori S; Ratzkin B; Yamamoto T
Oncogene; 1997 Jan; 14(4):439-49. PubMed ID: 9053841
[TBL] [Abstract][Full Text] [Related]
19. Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).
Settleman J
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S36-41. PubMed ID: 19393834
[TBL] [Abstract][Full Text] [Related]
20. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
